Results 81 to 90 of about 175,170 (271)

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

FEBS Open Bio, EarlyView.
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy, Arnaud Vigneron, Xavier Rousset, Jérome Guitton, Emmanuel Grolleau, Margaux Raffin, Julie Balandier, Gaëlle Lescuyer, Mathilde Bardou, Florence Geiguer, Sébastien Couraud, Claire Bardel, Jean Viallet, Nazim Benzerdjeb, Léa Payen   +14 more
wiley   +1 more source

Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment

Nature Communications
Immune cells must adapt to different environments during the course of an immune response. Here we study the adaptation of CD8+ T cells to the intestinal microenvironment and how this process shapes the establishment of the CD8+ T cell pool. CD8+ T cells
Matteo Villa, David E. Sanin, Petya Apostolova, Mauro Corrado, Agnieszka M. Kabat, Carmine Cristinzio, Annamaria Regina, Gustavo E. Carrizo, Nisha Rana, Michal A. Stanczak, Francesc Baixauli, Katarzyna M. Grzes, Jovana Cupovic, Francesca Solagna, Alexandra Hackl, Anna-Maria Globig, Fabian Hässler, Daniel J. Puleston, Beth Kelly, Nina Cabezas-Wallscheid, Peter Hasselblatt, Bertram Bengsch, Robert Zeiser, Sagar, Joerg M. Buescher, Edward J. Pearce, Erika L. Pearce   +26 more
doaj   +1 more source

A potential tumor suppressor role of PLK2 in glioblastoma

FEBS Open Bio, EarlyView.
PLK2 was consistently downregulated in GBM tissues. Overexpression of PLK2 in GBM cell lines U87MG and U251 reduced their tumorigenic potential and enhanced cell cycle arrest and apoptosis. Suggesting that PLK2 overexpression could potentially be leveraged as a therapeutic strategy to inhibit tumor progression and enhance apoptosis, providing new ...
Xiangping Xia, Peirui Wang, Hua Xiao, Qishan Ran, Yan Li, Shengtao Yao   +5 more
wiley   +1 more source

A primate-specific retroviral enhancer wires the XACT lncRNA into the core pluripotency network in humans

Nature Communications, 2019
XACT is a primate-specific TE-derived lncRNA that coats active X chromosomes in pluripotent cells and may contribute to species-specific regulation of X chromosome inactivation.
Miguel Casanova, Madeleine Moscatelli, Louis Édouard Chauvière, Christophe Huret, Julia Samson, Tharvesh Moideen Liyakat Ali, Olga Rosspopoff, Claire Rougeulle   +7 more
doaj   +1 more source

Epigenetic common opal from the Hawkesbury Sandstone Formation of the Sydney Basin [PDF]

, 1952
J. F. Lovering
openalex   +1 more source

Beyond digital twins: the role of foundation models in enhancing the interpretability of multiomics modalities in precision medicine

FEBS Open Bio, EarlyView.
This review highlights how foundation models enhance predictive healthcare by integrating advanced digital twin modeling with multiomics and biomedical data. This approach supports disease management, risk assessment, and personalized medicine, with the goal of optimizing health outcomes through adaptive, interpretable digital simulations, accessible ...
Sakhaa Alsaedi, Xin Gao, Takashi Gojobori   +2 more
wiley   +1 more source

Epigenetics-targeted drugs: current paradigms and future challenges

Signal Transduction and Targeted Therapy
Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA modification, histone modification, RNA modification, chromatin remodeling, and non-coding RNA regulation.
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, Renhao Guo, Peng Bai, Shuang Liu, Tingting Li, Yutao Jiang, Shuang Wei, Zhijing Na, Xue Xiao, Da Li   +11 more
doaj   +1 more source

Characterisation of the role played by ELMO1, GPR141 and the intergenic polymorphism rs918980 in Fuchs' dystrophy in the Indian population

FEBS Open Bio, EarlyView.
This study reports the upregulation of ELMO1 and GPR141 in human Fuchs' endothelial corneal dystrophy (FECD) corneal endothelium and ultraviolet A‐induced FECD mice model. A genetic association of an intergenic single nucleotide polymorphism rs918980 present between both genes is observed with FECD in the Indian population.
Susmita Sharma, Samar Kumar Basak, Sujata Das, Debasmita Pankaj Alone   +3 more
wiley   +1 more source

A Genetic Programming System with an Epigenetic Mechanism for Traffic Signal Control [PDF]

arXiv, 2019
Traffic congestion is an increasing problem in most cities around the world. It impacts businesses as well as commuters, small cities and large ones in developing as well as developed economies. One approach to decrease urban traffic congestion is to optimize the traffic signal behaviour in order to be adaptive to changes in the traffic conditions ...
arxiv